Patient: Page 24

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Patient Pipeline

    CLINICAL TRIAL RECRUITMENT AND ENROLLMENT EFFORTS ARE OFTEN NOT GIVEN HIGH PRIORITY, causing costly delays in the develop ment of new drugs. Unfortunately, there are no quick fixes, but companies are beginning to institute wellthought out and designed processes to bring the right patients to the ...

    By PharmaVoice Team • Jan. 18, 2010
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Industry Heal Thyself

    The right MEDICINE TREWHITT. More than a year ago, key members of PhRMA’s executive board identified that there was a need to revisit the guidelines and make some improvements to eliminate the periodic complaints and allegations about the practices of sales representatives and their relationships...

    By PharmaVoice Team • Jan. 11, 2010
  • drug shopping cart Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Salesforce of the Future

    Our experts agree: the salesforce of the future will be more specialized, more technically advanced, and more clinically savvy; oh, and there will be fewer feet on the street, finally. If the past year is any indication, the salesforce of the future is going to experience an extreme makeover. For...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    R&D Business Models

    The Changing R&D Business Model Companies throughout the industry are experimenting with new models designed to tackle the pipeline productivity challenge. harmaceutical research and development is facing many pressures, from decreased productivity to the impact of the economy to changing tec...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Emerging Markets Poised for Growth

    Emerging markets are growing in size and in importance for drug developers. Countries outside the traditional markets of the United States, Europe, and Japan are revamping their regulatory and legal systems and reforming their healthcare systems, and they are expected to contribute more to the gl...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    CRM: Connecting the Dots...

    CUSTOMER RELATIONSHIP MANAGEMENT BY TAREN GROM CRM requires a multilevel, enterprisewide view of customers — thereby demanding a strong customer data management business practice . A 5% increase in customer retention can lead to a 25% to 85% profit increase,depending on the industry. — HarvardBus...

    By PharmaVoice Team • Nov. 4, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    E-learning: A Virtual Classroom

    Pharmaceutical companies are jumping on board the etrain as a way to better manage their internal learning initiatives The THE CLICK MAY NEVER REPLACE THE NO. 2 PENCIL, but elearning is becoming the teacher’s pet in terms of reach, content flexibility, access, and alleviating outofoffice downtime...

    By PharmaVoice Team • Nov. 2, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Sales Reps — What's Up Doc?

    The relationship between the pharmaceutical sales representative and the physician has undergone a dramatic shift in recent years. In the past, the sales representative provided value to the physician, had an established and meaningful rela tionship, engaged in an interactive dialog, and acted as...

    By PharmaVoice Team • Nov. 2, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Creating Opportunity From Diversity

    bring messages about their products to diverse groups in a way that is culturally sensitive, that will garner longterm goodwill of the communities, and that address the most press ing health concerns facing various racial and ethnic groups. Developing diverse marketing promotions and programs whe...

    By PharmaVoice Team • Nov. 2, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Planting the Seeds of a Blockbuster

    Until fairly recently, top tier pharmaceutical companies obtained license rights to a product developed by a biotechnology company, thereby infusing much needed capital for furtherance of clinical research. In return, the pharmaceutical company obtained outright or major ity rights to marketing a...

    By PharmaVoice Team • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Coming Into Focus

    The pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according t...

    By PharmaVoice Team • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Beyond the Genome — Proteomics

    Drug discovery in the postgenomic era will lead researchers to focus on the proteins and biological mechanisms that cause disease as a way to develop new types of treatments that are safer and more effective BY DENISE MYSHKO When the initial map of the human genome was first published in February...

    By PharmaVoice Team • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Knowledge Revolution

    In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...

    By PharmaVoice Team • Aug. 24, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Creative Challenge

    BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...

    By PharmaVoice Team • Aug. 12, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Vanlev: Coming Soon

    In a second round for a drug that once was predicted to become a high flier, BristolMyers Squibb is one FDA approval away from launching the next best medication for the treatment of hypertension, a condition that affects about 50 million Americans. Nearly two years ago, BristolMyers Squibb was s...

    By PharmaVoice Team • Aug. 12, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Consumer shifts demand changes in healthcare marketing In its latest report on market insights, Cheskin, a strategic market research and consulting company, defines three consumer trends that are driving the evolution of the healthcare and lifesci ences industry: consumer enlightenment and empowe...

    By PharmaVoice Team • March 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    GLOBAL Development

    BY DENISE MYSHKO Drug developers are looking to emerging markets and increasing their outsourcing efforts as ways to access expertise and reach. Pharmaceutical companies will continue to globalize their preclinical and clinical development activities to increase speed-to-market and expand their p...

    By PharmaVoice Team • Feb. 26, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Buying Big GLOBAL

    How M&A Impacts the Pharma Market As patent expirations and dwindling pipelines, along with an embattled economy, put a dent on pharma profits, acquisitions again become a necessity for large pharma companies seeking to maintain a healthy bottom line. With Pfizer’s purchase of Wyeth, among ot...

    By PharmaVoice Team • Feb. 26, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Venture Capital: Funding Challenges

    VENTURE CAPITAL: CAUTIOUS investment Venture capital firms are sitting on massive funds and are still doing deals, but their energies are focused on reinvesting in portfolio companies and safer latest age deals. As a result, it has never been harder for the early stage pure startup to get funded....

    By PharmaVoice Team • Feb. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    A Community Approach

    As many pharmaceutical companies are finding, healthcare begins within the community, and a regional program, with health information that helps patients at a local level, might just win a company the hearts, minds, and ultimately buying power of those community members. For an industry confronte...

    By PharmaVoice Team • Feb. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Delivering on the Promise

    BY ELISABETH PENA Drug delivery promises FULLER PIPELINES, EXTENDED PRODUCT LIFE CYCLES, and IMPROVED PATIENT COMPLIANCE. AS THE PHARMACEUTICAL INDUSTRY FACES A FLOOD OF BLOCKBUSTER DRUG PATENT EXPIRATIONS, drug-delivery COMPANIES WILL HAVE THE CHANCE TO PROVE THEMSELVES. BY 2005 analysts predict...

    By PharmaVoice Team • Feb. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    NEW HEALTHCARE-RELATED PRODUCTS, SERVICES, AND COMPANIES NOP World Health Forms a New Division to RESPOND TO PHARMACEUTICAL PUBLIC-RELATIONS CRISES Through a combination of in-depth therapeutic class analyses, events-driven Web research, and multi-stake holder image tracking and reputation assess...

    By PharmaVoice Team • Feb. 22, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Information Technology: Tracking the E-Volution

    Pharmaceutical companies have long term plans, they have products that take a long time to develop, a long time to test to gain approval, and they have a shelf life. But technology moves so much faster than that. So the industry as a whole has had to adopt to the speed of technology. IAN CROSS BY...

    By PharmaVoice Team • Feb. 21, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Practice of Public Relations

    When effectively managed, public relations creates unique opportunities for marketers to provide con sumers and healthcare professionals with immediate and thorough drug and healthcare information. The healthcare publicrelations market in the United States grew 30% last year and is now valued at ...

    By PharmaVoice Team • Feb. 21, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    No Pens or Mugs? No Problem.

    The industry is discovering it won’t lose its ability to message effectively under the new PhRMA code. Under the new PhRMA code, the exhibit hall of the future will contain no tchotchkes. Sales reps will no longer stop by the physician’s office with donuts, pens, and sticky notes. The question is...

    By PharmaVoice Team • Dec. 22, 2008